Deeply cultivating chemical synthesis platforms and synthetic biology for many years, adhering to technological innovation to drive enterprise development
Persist in independent development and application, continuously iterate and innovate processes
Evaluation and design of process, production optimization, and scale-up for commercialization
Research on the purity, impurities, crystal form, particle size, and GTls(genotoxic impurities) of API(Active pharmaceutical ingredient), analytical method development, transfer and validation,formulation of quality standards, and stability assessment
Halogenation reaction, hydrogenation reaction, enzymatic catalysis, asymmetric catalysis, Grignard reaction, etc
Suzhou Nordica Biopharma Co., Ltd is a technology-driven and innovative enterprise dedicated to the research, development, production, sales of bio-pharmaceuticals and new chemical materials. Headquartered in Suzhou High tech Zone, with modern production bases and research and development centers.
Our main products covers multiple fields such as diabetes, oncology, neurological diseases, cardiovascular diseases, and anti-infectives. We have a highly skilled R&D team and collaborate with renowned research institutes and universities, committed to the R&D of pharmaceutical intermediates and material, continuously launching products with independent intellectual property rights and competitiveness.
A strict quality control system has been established to ensure the quality of products and timely delivery of orders. Our sales team has provided high-quality and professional services for both domestic and foreign customers more than 10 years in chemical industry.
Suzhou Nordica Biopharma Co., Ltd adheres to the business philosophy of "creating value, win-win and common prosperity", takes technological innovation as the driving force, continuously improves product quality and technological level, and striving to become a leading technology-driven innovative company.
We are willing to cooperate with friends from all sectors to contribute to the development of China’s bio-pharmaceutical industry.
Many electric car owners are concerned that their batteries may not be durable in very cold weather. Scientists have developed a new and safer electrolyte for lithium-ion batteries, which may solve this problem by withstanding extremely low temperatures.
ALD and CVD are thin film deposition techniques that facilitate the deposition of thin films on substrates. The main difference between the two technologies lies in the way they deposit thin films. The main difference between ALD and CVD is that atomic layer deposition (ALD) deposits a thin film of one atomic layer at a time, while CVD can deposit a wider range of thin films.
The production of peptides is generally divided into two methods: chemical synthesis and biosynthesis. Whether it is chemical synthesis or biosynthesis, the production of peptides requires strict control of reaction conditions, purification steps, and quality testing to ensure the purity and quality of peptides.
.png)
